191 related articles for article (PubMed ID: 22475955)
1. [Post-transfusional iron overload, iron loading anemia].
Rose C
Rev Med Interne; 2012 Jun; 33 Suppl 1():S15-8. PubMed ID: 22475955
[No Abstract] [Full Text] [Related]
2. Iron chelation therapy for transfusional iron overload: a swift evolution.
Musallam KM; Taher AT
Hemoglobin; 2011; 35(5-6):565-73. PubMed ID: 21910602
[TBL] [Abstract][Full Text] [Related]
3. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
Balocco M; Carrara P; Pinto V; Forni GL
Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
[No Abstract] [Full Text] [Related]
4. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of ICL670, a once-daily oral iron chelator in a phase III clinical trial of beta-thalassemia patients with transfusional iron overload.
Galanello R
Ann N Y Acad Sci; 2005; 1054():183-5. PubMed ID: 16339664
[TBL] [Abstract][Full Text] [Related]
6. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
El-Beshlawy A; Manz C; Naja M; Eltagui M; Tarabishi C; Youssry I; Sobh H; Hamdy M; Sharaf I; Mostafa A; Shaker O; Hoffbrand AV; Taher A
Ann Hematol; 2008 Jul; 87(7):545-50. PubMed ID: 18351337
[TBL] [Abstract][Full Text] [Related]
7. [Pathogenesis of transfusional iron overload and iron chelation therapy].
Ozawa K
Rinsho Ketsueki; 2009 Jul; 50(7):527-31. PubMed ID: 19638719
[No Abstract] [Full Text] [Related]
8. Iron chelation therapy for non-transfusion-dependent thalassemia (NTDT): a status quo.
Taher AT; Musallam KM; Viprakasit V; Porter JB; Cappellini MD
Blood Cells Mol Dis; 2014; 52(2-3):88-90. PubMed ID: 24041597
[No Abstract] [Full Text] [Related]
9. Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.
Leitch HA
Drugs; 2011 Jan; 71(2):155-77. PubMed ID: 21275444
[TBL] [Abstract][Full Text] [Related]
10. Management of chronic iron overload.
Baxter B
Paediatr Nurs; 2002 Sep; 14(7):14-6. PubMed ID: 12271869
[No Abstract] [Full Text] [Related]
11. Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload.
Gattermann N
Leuk Res; 2007 Dec; 31 Suppl 3():S10-5. PubMed ID: 18037413
[TBL] [Abstract][Full Text] [Related]
12. Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes.
Goldberg SL
Leuk Res; 2007 Dec; 31 Suppl 3():S16-22. PubMed ID: 18037414
[TBL] [Abstract][Full Text] [Related]
13. Post-transfusional iron overload in the haemoglobinopathies.
Thuret I
C R Biol; 2013 Mar; 336(3):164-72. PubMed ID: 23643400
[TBL] [Abstract][Full Text] [Related]
14. Iron overload and chelation.
Hershko C; Link G; Konijn AM; Ioav Cabantchik Z
Hematology; 2005; 10 Suppl 1():171-3. PubMed ID: 16188664
[TBL] [Abstract][Full Text] [Related]
15. Iron deficiency and overload.
Beutler E; Hoffbrand AV; Cook JD
Hematology Am Soc Hematol Educ Program; 2003; ():40-61. PubMed ID: 14633776
[TBL] [Abstract][Full Text] [Related]
16. Iron overload and toxicity: the hidden risk of multiple blood transfusions.
Shander A; Cappellini MD; Goodnough LT
Vox Sang; 2009 Oct; 97(3):185-97. PubMed ID: 19663936
[TBL] [Abstract][Full Text] [Related]
17. Evaluation and treatment of transfusional iron overload in children.
Ware HM; Kwiatkowski JL
Pediatr Clin North Am; 2013 Dec; 60(6):1393-406. PubMed ID: 24237978
[TBL] [Abstract][Full Text] [Related]
18. Iron chelation therapy for patients with sickle cell disease and iron overload.
Inati A; Khoriaty E; Musallam KM; Taher AT
Am J Hematol; 2010 Oct; 85(10):782-6. PubMed ID: 20721892
[No Abstract] [Full Text] [Related]
19. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.
Kattamis A; Kassou C; Berdousi H; Ladis V; Papassotiriou I; Kattamis C
Haematologica; 2003 Dec; 88(12):1423-5. PubMed ID: 14687998
[No Abstract] [Full Text] [Related]
20. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention.
Kwiatkowski JL; Cohen AR; Garro J; Alvarez O; Nagasubramanian R; Sarnaik S; Thompson A; Woods GM; Schultz W; Mortier N; Lane P; Mueller B; Yovetich N; Ware RE;
Am J Hematol; 2012 Feb; 87(2):221-3. PubMed ID: 22120913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]